Browsing by Author "Matulonis, Ursula"

Now showing items 1-10 of 10

    • Angiogenic mRNA and microRNA Gene Expression Signature Predicts a Novel Subtype of Serous Ovarian Cancer 

      Risch, Thomas; Fan, Jian-Bing; Holton, Kristina; Rubio, Renee; April, Craig; Wickham-Garcia, Eliza; Bentink, Stefan; Haibe-Kains, Benjamin; Hirsch, Michelle S.; Chen, Jing; Liu, Joyce; Culhane, Aedin; Drapkin, Ronny I.; Quackenbush, John; Matulonis, Ursula Anne (Public Library of Science, 2012)
      Ovarian cancer is the fifth leading cause of cancer death for women in the U.S. and the seventh most fatal worldwide. Although ovarian cancer is notable for its initial sensitivity to platinum-based therapies, the vast ...

    • Association and prognostic significance of BRCA1/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1/PD-L1 in high grade serous ovarian cancer 

      Strickland, Kyle C.; Howitt, Brooke E.; Shukla, Sachet A.; Rodig, Scott; Ritterhouse, Lauren L.; Liu, Joyce F.; Garber, Judy E.; Chowdhury, Dipanjan; Wu, Catherine J.; D'Andrea, Alan D.; Matulonis, Ursula A.; Konstantinopoulos, Panagiotis A. (Impact Journals LLC, 2016)
      Immune checkpoint inhibitors (e.g., anti-PD-1 and anti-PD-L1 antibodies) have demonstrated remarkable efficacy against hypermutated cancers such as melanomas and lung carcinomas. One explanation for this effect is that ...

    • Association of Polymerase e–Mutated and Microsatellite-Instable Endometrial Cancers With Neoantigen Load, Number of Tumor-Infiltrating Lymphocytes, and Expression of PD-1 and PD-L1 

      Howitt, Brooke Elizabeth; Shukla, Sachet; Sholl, Lynette Marie; Ritterhouse, Lauren Lee; Watkins, Jaclyn Christine; Rodig, Scott J.; Stover, Elizabeth Harmon; Strickland, Kyle Craig; D'Andrea, Alan David; Wu, Catherine Ju-Ying; Matulonis, Ursula Anne; Konstantinopoulos, Panagiotis (American Medical Association (AMA), 2015)
      Importance Immune checkpoint inhibitor therapy has shown benefit in various cancers, but their potential in endometrial cancer (EC) is unknown. Observations Prediction of neoantigen load was performed using sequencing ...

    • CA125 Immune Complexes in Ovarian Cancer Patients with Low CA125 Concentrations 

      Cramer, Daniel William; O'Rourke, D. J.; Vitonis, A. F.; Matulonis, Ursula Anne; DiJohnson, D. A.; Sluss, Patrick M.; Crum, Christopher Paul; Liu, B. C.- S. (American Association for Clinical Chemistry (AACC), 2010)
      BACKGROUND About 20% of women with ovarian cancer have low concentrations of serum cancer antigen 125 (CA125), and this important tumor marker cannot be used to monitor their disease. The measured concentration for mucin ...

    • Current Status and Evolution of Preclinical Drug Development Models of Epithelial Ovarian Cancer 

      Konstantinopoulos, Panagiotis A.; Matulonis, Ursula A. (Frontiers Media S.A., 2013)
      Epithelial ovarian cancer (EOC) is the most lethal gynecologic malignancy and the fifth most common cause of female cancer death in the United States. Although important advances in surgical and chemotherapeutic strategies ...

    • Detection of ERBB2 Amplification in Uterine Serous Carcinoma by Next-Generation Sequencing: An Approach Highly Concordant With Standard Assays 

      Robinson, Carrie; Harrison, Beth; Ligon, Azra; Dong, Fei; Maffeis, Valeria; Matulonis, Ursula; Nucci, Marisa; Kolin, David L. (Springer Science and Business Media LLC, 2020-10-19)
      Uterine serous carcinoma is an aggressive subtype of endometrial cancer that accounts for fewer than 10% of endometrial carcinomas but is responsible for about half of deaths. A subset of cases has HER2 overexpression ...

    • Influence of Patients' Preferences and Treatment Site on Cancer Patients' End-of-Life Care 

      Wright, Alexi Anne; Mack, Jennifer Williams; Kritek, Patricia A.; Balboni, Tracy; Massaro, Anthony Francis; Matulonis, Ursula Anne; Block, Susan Dale; Prigerson, Holly (Wiley-Blackwell, 2010)
      BACKGROUND: Research suggests that patients' end-of-life (EOL) care is determined primarily by the medical resources available, and not by patient preferences. The authors examined whether patients' desire for life-extending ...

    • Profiles of Genomic Instability in High-Grade Serous Ovarian Cancer Predict Treatment Outcome 

      Wang, Z. C.; Birkbak, N; Culhane, Aedin; Drapkin, R; Fatima, Aquila; Tian, R; Schwede, M.; Alsop, K.; Daniels, K. E.; Piao, H.; Liu, Joy; Etemadmoghadam, D.; Miron, A; Salvesen, H. B.; Mitchell, G.; DeFazio, A.; Quackenbush, John; Berkowitz, Ross Stuart; Iglehart, James Dirk; Bowtell, D. D. L.; Matulonis, Ursula Anne (American Association for Cancer Research (AACR), 2012)
      Purpose—High-grade serous cancer (HGSC) is the most common cancer of the ovary and is characterized by chromosomal instability. Defects in homologous recombination repair (HRR) are associated with genomic instability in ...

    • A single-cell and single-nucleus RNA-Seq toolbox for fresh and frozen human tumors 

      Slyper, Michal; Porter, Caroline; Ashenberg, Orr; Waldman, Julia; Drokhlyansky, Eugene; Wakiro, Isaac; Smilie, Christopher; Smith-Rosario, Gabriela; Wu, Jingyi; Dionne, Danielle; Vigneau, Sebastien; Jane-Valbuena, Judit; Tickle, Timothy; Napolitano, Sara; Su, Mei-Ju; Patel, Anand; Karlstrom, Asa; Gristch, Simon; Nomura, Masashi; Waghray, Avinash; Gohil, Satyen; Tsankov, Alexander; Jerby-Arnon, Livnat; Cohen, Ofir; Klughammer, Johanna; Rosen, Yanay; Gould, Joshua; Nguyen, Lan; Hofree, Matan; Tramontozzi, Peter; Levy, Rachel; Li, Bo; Wu, Catherine; Izar, Benjamin; Haq, Rizwan; Hodi, Stephen; Yoon, Charles; Hata, Aaron; Baker, Suzanne; Suva, Mario; Bueno, Raphael; Stover, Elizabeth; Clay, Michael; Dyer, M Aiven; Collins, Natalie; Matulonis, Ursula; Wagle, Nikhil; Johnson, Bruce; Rotem, Asaf; Rozenblatt-Rosen, Orit; Regev, Aviv (Springer Science and Business Media LLC, 2020-05-01)
      Single-cell genomics is essential to chart tumor ecosystems. Although single-cell RNA-Seq (scRNA-Seq) profiles RNA from cells dissociated from fresh tumors, single-nucleus RNA-Seq (snRNA-Seq) is needed to profile frozen ...

    • Sublethal concentrations of 17-AAG suppress homologous recombination DNA repair and enhance sensitivity to carboplatin and olaparib in HR proficient ovarian cancer cells 

      Choi, Young Eun; Battelli, Chiara; Watson, Jacqueline; Liu, Joyce; Curtis, Jennifer; Morse, Alexander N.; Matulonis, Ursula A.; Chowdhury, Dipanjan; Konstantinopoulos, Panagiotis A. (Impact Journals LLC, 2014)
      The promise of PARP-inhibitors(PARPis) in the management of epithelial ovarian cancer(EOC) is tempered by the fact that approximately 50% of patients with homologous recombination (HR)-proficient tumors do not respond well ...